CD163 and glioma: Treatment with an anti-programmed death-ligand 1 (PD-L1) antibody has demonstrated a significant reduction of CD163+ macrophage infiltration in glioma, implying a potential relationship between CD163 expression and immune checkpoint mechanisms [171].